Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Single-Blind, Superiority Study Comparing The Efficacy And Tolerability Of A New Drug Containing The Combination Meloxicam And Cyclobenzaprine And The Same Components Alone In The Treatment Of Acute Lumbago

Trial Profile

A Phase III, Randomized, Single-Blind, Superiority Study Comparing The Efficacy And Tolerability Of A New Drug Containing The Combination Meloxicam And Cyclobenzaprine And The Same Components Alone In The Treatment Of Acute Lumbago

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclobenzaprine/meloxicam (Primary) ; Cyclobenzaprine; Meloxicam
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors Eurofarma
  • Most Recent Events

    • 29 Apr 2016 Status changed from not yet recruiting to withdrawn prior to enrolment because the comparator product was withdrawn from the brazilian market not being possible to conduct the design regarding initially planned
    • 24 Jul 2015 Planned primary completion date changed from 1 Jun 2013 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
    • 24 Jul 2015 Planned End Date changed from 1 Sep 2013 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top